Sanjivani Paranteral Ltd Drops 16.53%: 4 Key Factors Behind the Steep Decline

46 minutes ago
share
Share Via
Sanjivani Paranteral Ltd experienced a steep decline of 16.53% over the week ending 15 May 2026, closing at Rs.136.30 from Rs.163.30 the previous Friday. This underperformance was significantly sharper than the Sensex’s 2.63% fall during the same period, reflecting a challenging week marked by valuation shifts, earnings concerns, and technical weakness despite some positive fundamental signals.

Key Events This Week

11 May: Stock opens at Rs.157.45, down 3.58% amid broad market weakness

12 May: Further decline to Rs.149.90, MarketsMOJO upgrades rating to Hold

13 May: Valuation metrics improve but stock remains volatile, closes at Rs.152.40 (+1.67%)

15 May: Sharp fall to 52-week low of Rs.128.20, Q4 FY26 results reveal profit decline

Week Open
Rs.163.30
Week Close
Rs.136.30
-16.53%
Week Low
Rs.128.20
Sensex Change
-2.63%

11 May 2026: Market Weakness Sets Negative Tone

Sanjivani Paranteral opened the week at Rs.157.45, down 3.58% from the previous close, reflecting broad market weakness as the Sensex fell 1.40% to 35,679.54. The stock’s volume was moderate at 13,853 shares. This initial decline set a cautious tone for the week, with the stock underperforming the benchmark index by over two percentage points.

12 May 2026: Rating Upgrade Amid Continued Price Pressure

Despite the stock falling further to Rs.149.90 (-4.80%), MarketsMOJO upgraded Sanjivani Paranteral’s rating from Sell to Hold on 12 May 2026. The upgrade was driven by improved valuation metrics and financial performance, signalling a more optimistic outlook despite recent price weakness. The Sensex declined 2.19% to 34,899.09, indicating a challenging environment for equities. Volume dropped to 5,550 shares, suggesting reduced trading interest amid the downtrend.

Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!

  • - Sustainable profitability reached
  • - Post-turnaround strength
  • - Comeback story unfolding

Be Early to the Comeback →

13 May 2026: Valuation Improvements Temper Volatility

The stock rebounded modestly to Rs.152.40 (+1.67%) on 13 May 2026, supported by the announcement of an upgrade to Hold and improved valuation parameters. The price-to-earnings ratio stood at 21.67, lower than many sector peers, while the EV/EBITDA multiple was a moderate 16.69. These metrics suggested renewed price attractiveness despite the stock’s recent underperformance. The Sensex gained 0.32% to 35,010.26, providing a relatively stable backdrop. However, trading volume was low at 2,273 shares, indicating limited conviction behind the bounce.

14 May 2026: Minor Setback Amid Sector Strength

Sanjivani Paranteral slipped back to Rs.149.90 (-1.64%) on 14 May, as the Sensex advanced 1.01% to 35,364.44. The stock’s volume increased to 5,939 shares, but the price decline contrasted with broader market gains, highlighting ongoing investor caution. The company’s valuation remained attractive relative to peers, but short-term technical signals suggested resistance near the Rs.150 level.

15 May 2026: Sharp Decline to 52-Week Low on Earnings Concerns

The week ended with a dramatic fall to Rs.136.30 (-9.07%), including an intraday low of Rs.128.20, marking a new 52-week low. This sharp decline followed the release of Q4 FY26 results revealing a steep 73.6% drop in net profit after tax to Rs.0.55 crore, alongside the lowest recent net sales of Rs.13.21 crore and a PBDIT of Rs.1.58 crore. The stock underperformed the Sensex, which fell 0.36% to 35,236.50. Volume surged to 75,293 shares, reflecting heavy selling pressure. Technical indicators showed the stock trading below all key moving averages, signalling sustained bearish momentum. The broader pharmaceutical sector, by contrast, was resilient, with the NIFTY PHARMA index hitting a 52-week high on the same day.

Is Sanjivani Paranteral Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!

  • - Better alternatives suggested
  • - Cross-sector comparison
  • - Portfolio optimization tool

Find Better Alternatives →

Weekly Price Performance: Sanjivani Paranteral vs Sensex

Date Stock Price Day Change Sensex Day Change
2026-05-11 Rs.157.45 -3.58% 35,679.54 -1.40%
2026-05-12 Rs.149.90 -4.80% 34,899.09 -2.19%
2026-05-13 Rs.152.40 +1.67% 35,010.26 +0.32%
2026-05-14 Rs.149.90 -1.64% 35,364.44 +1.01%
2026-05-15 Rs.136.30 -9.07% 35,236.50 -0.36%

Key Takeaways

Valuation Upgrade Amid Price Weakness: The MarketsMOJO upgrade from Sell to Hold on 12 May 2026 was driven by improved valuation metrics, including a P/E ratio of 21.67 and EV/EBITDA of 16.69, which are attractive relative to sector peers. This suggests the stock is trading at a discount despite recent price declines.

Sharp Earnings Decline Weighs on Sentiment: The Q4 FY26 results released on 15 May revealed a 73.6% drop in net profit and weak sales, which triggered a steep price fall to a 52-week low. This earnings contraction raises concerns about near-term profitability and growth sustainability.

Technical Weakness and High Volatility: The stock’s price closed below all major moving averages and showed bearish momentum indicators, signalling continued downside risk. The surge in volume on the last trading day indicates strong selling pressure.

Sector Outperformance Highlights Relative Underperformance: While Sanjivani Paranteral declined sharply, the broader pharmaceutical sector remained resilient, with the NIFTY PHARMA index reaching new highs. This divergence underscores company-specific challenges amid a generally positive sector environment.

Conclusion

Sanjivani Paranteral Ltd’s 16.53% weekly decline reflects a complex interplay of improved valuation appeal offset by disappointing quarterly earnings and technical weakness. The MarketsMOJO upgrade to Hold recognises better financial metrics and valuation discounts, but the sharp profit fall and sustained price pressure highlight significant near-term challenges. The stock’s underperformance relative to the Sensex and its sector peers emphasises the risks inherent in this micro-cap pharmaceutical company. Investors should closely monitor upcoming financial updates and price action to gauge whether the improving fundamentals can translate into a sustained recovery.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News